Vancouver, British Columbia, May 25, 2005 - Response Biomedical Corp. (TSX-V: RBM, OTCBB: RPBIF), today announced it has received both the 2005 Excellence in Technology of the Year Award and 2005 Product Innovation of the Year Award for its RAMP System from Frost & Sullivan, a premier growth consulting company worldwide.

"This portable immunoassay-based diagnostic platform provides laboratory quality detection of several biological agents to first responders operating in the field in less than 15 minutes, compared to several days that are required by expensive, confirmatory immunoassay tests run in today's laboratories," says Barath Shankar, Healthcare analyst for Frost & Sullivan. "RAMP also has broad applications in a variety of clinical and environmental diagnostic testing markets where rapid and highly sensitive information improves patient outcomes and considerably reduces administrative costs."

"Frost & Sullivan is widely regarded as one of the world's most credible and influential independent industry research organizations by the business and investment community internationally. It is a tremendous honor for Response to be recognized with two distinct technology awards over competing candidates from around the world," says Mr. Bill Radvak, President and CEO. "In addition to our recent collaborations with 3M Health Care, General Dynamics Canada and Shionogi, these awards further validate the Company's RAMP System as the leading technology platform in the US$5 billion worldwide rapid quantitative immunoassay Point-of-Care market."

The Frost & Sullivan Award for Product Innovation of the Year is presented annually to the company that has demonstrated excellence in new products and technologies within their industry. Response has shown innovation by launching a broad line of emerging products based on its proprietary RAMP technology. Response also earned Frost & Sullivan's 2005 Excellence in Technology of the Year Award in the field of biological agent detection and analysis for its overall excellence in technology development, evidenced by 16 months of independent validation testing conducted by AOAC International and sponsored by the U.S. Department of Homeland Security.

To choose the Award recipients, Frost & Sullivan's analyst teams track technology innovation in key hi-tech markets, all new product launches, R&D spending, products in development, and new product features and modifications. The selection process includes primary participant interviews and extensive primary and secondary research using a bottom-up approach. The analyst teams shortlist candidates on the basis of a set of qualitative and quantitative measurements. The analysts also consider the pace of technology innovation, the potential relevance or significance of the technology to the overall industry. The Award recipients are chosen after a thorough evaluation of this research.

About Response Biomedical Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP System for clinical and environmental applications. RAMP represents a new paradigm in diagnostic testing by providing reliable information in minutes, anywhere, every time. The RAMP System consists of a portable fluorescent Reader and single-use, disposable Test Cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP tests are commercially available for the early detection of heart attack, environmental detection of West Nile virus, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. The Company has achieved CE Mark and its Quality Management System is registered to ISO 13485: 1996 and ISO 9000: 2000.

Response Biomedical is a publicly traded company, listed on the TSX Venture Exchange under the trading symbol "RBM", and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

About Frost & Sullivan Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training toentify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

Frost & Sullivan Hall of Fame The TSX Venture Exchange and OTC Bulletin Board have not reviewed and do not accept responsibility for the adequacy of the content of the information contained herein. The statements made in this press release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

Contact: Don Bradley Director, Corporate Communications, Response Biomedical Corp. Tel (604) 681- 4101 ext 202 E-mail: dbradley@responsebio.com

Stacie Jones Corporate Communications Executive Frost & Sullivan Tel (210) 247-2450 Email: Stacie.Jones@frost.com